SV1, in which thefirst three exons of GHRHR are replaced with a fragment of intron3, inducing a novel in-frame start codon, is known to have ligand-independentactivity and is believed to confer growth-stimulating effects in manytumor tissues.15 GHRHR peptide antagonists(which block GHRH-induced and/or ligand-independent receptor activity)have been shown to inhibit growth of various cancer cell lines inaddition to showing benefits in models of prostate,16 breast,17 pancreatic,18 gastric,19 and ovarian7,20 cancer. This evidence concerns the gene GHRH and cancer.